The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

BACKGROUND/AIMS: The therapeutic options for metastatic neuroendocrine tumors (NETs) are limited. As PI3K signaling is often activated in NETs, we have assessed the effects of selective PI3Kp110α inhibition by the novel agent BYL719 on cell viability, colony formation, apoptosis, cell cycle, signali...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: Nölting, Svenja, Rentsch, Jakob, Freitag, Helma, Detjen, Katharina, Briest, Franziska, Möbs, Markus, Weissmann, Victoria, Siegmund, Britta, Auernhammer, Christoph J., Aristizabal Prada, Elke Tatjana, Lauseker, Michael, Grossman, Ashley, Exner, Samantha, Fischer, Christian, Grötzinger, Carsten, Schrader, Jörg, Grabowski, Patricia
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2017
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553670/
https://ncbi.nlm.nih.gov/pubmed/28800359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0182852
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires